Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis

Emberesh, Myesa; Rubinstein, Jeremy D.; Young, John P.; Benoit, Stefanie; Dandoy, Christopher E.; Weiss, Brian

doi:10.1002/pbc.28852

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there is a lack of clear recommended time for adjuvant chemotherapy after NB surgery, many studies have suggested that postoperative adjuvant chemotherapy should be carried out as early as possible [ 24 , 25 ]. Emberesh [ 26 ] reported that there was a delay of systematic treatment (including chemotherapy, radiotherapy and immunotherapy) in 2 children with high-risk NB. Even if they subsequently received targeted immunotherapy, they did not escape the recurrence and progression of tumor.…”

Section: Discussionmentioning

confidence: 99%

Risk factors, impact and treatment of postoperative lymphatic leakage in children with abdominal neuroblastoma operated on by laparotomy

Feng,

Mou,

Yang

et al. 2024

BMC Surg

View full text Add to dashboard Cite

Background Lymphatic leakage is one of the postoperative complications of neuroblastoma. The purpose of this study is to summarize the clinical characteristics and risk factors of lymphatic leakage and try to find effective prevention and treatment measures. Methods A retrospective study included 186 children with abdominal neuroblastoma, including 32 children of lymphatic leakage and 154 children of non-lymphatic leakage. The clinical information, surgical data, postoperative abdominal drainage, treatment of lymphatic leakage and prognosis of the two groups were collected and analyzed. Results The incidence of lymphatic leakage in this cohort was 14% (32 children). Through univariate analysis of lymphatic leakage group and non-lymphatic leakage group, we found that lymphatic leakage increased the complications, prolonged the time of abdominal drainage and hospitalization, and delayed postoperative chemotherapy (p < 0.05). In this cohort, the median follow-up time was 46 (95% CI: 44–48) months. The follow-up data of 7 children were partially missing. 147 children survived, of which 23 had tumor recurrence (5 children recurred in the surgical area). 37 children died, of which 32 had tumor recurrence (9 children recurred in the operation area). In univariate analysis, there was no statistical difference in overall survival (p = 0.21) and event-free survival (p = 0.057) between lymphatic leakage group and non-lymphatic leakage group, while 3-year cumulative incidence of local progression was higher in lymphatic leakage group (p = 0.015). However, through multivariate analysis, we found that lymphatic leakage did not affect event-free survival, overall survival and cumulative incidence of local progression in children with neuroblastoma. Resection of 5 or more lymphatic regions was an independent risk factor for lymphatic leakage after neuroblastoma surgery. All 32 children with lymphatic leakage were cured by conservative treatment without surgery. Of these, 75% (24/32) children were cured by fat-free diet or observation, 25% (8/32) children were cured by total parenteral nutrition. The median drain output at diagnosis in total parenteral nutrition group was higher than that in non-total parenteral nutrition group (p < 0.001). The cut-off value was 17.2 ml/kg/day. Conclusions Lymphatic leakage does not affect the prognosis of children with neuroblastoma, but long-term drain output caused by lymphatic leakage will still adversely affect postoperative complications and follow-up treatment, which requires attention and active treatment measures. More attention should be paid to the children with 5 or more lymphatic regions resection, and the injured lymphatic vessels should be actively found and ligated after tumor resection to reduce the postoperative lymphatic leakage. Early application of total parenteral nutrition is recommended for those who have drain output at diagnosis of greater than 17.2 ml/kg/day. Level of evidence Level III, Treatment study (Retrospective comparative study).

show abstract

Section: Discussionmentioning

confidence: 99%

Risk factors, impact and treatment of postoperative lymphatic leakage in children with abdominal neuroblastoma operated on by laparotomy

Feng,

Mou,

Yang

et al. 2024

BMC Surg

View full text Add to dashboard Cite

show abstract

“… 18 , 19 Second, although GD2 is an ideal target for NB therapy because it is highly expressed on NB tumor cells, it also exists in other normal tissues. 20 , 21 Therefore, dinutuximab stimulates normal GD2 + cells, causing severe pain, fever, low platelet count, infusion reactions, hypotension, elevated liver enzymes, anemia, diarrhea, hypokalemia, capillary-leak syndrome, neutropenia, and lymphopenia. Dinutuximab treatment may result in nerve damage, infections, eye problems, electrolyte abnormalities, and bone marrow suppression.…”

Section: Introductionmentioning

confidence: 99%

A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics

Zhang

Wang

Zhu

et al. 2021

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Because current mainstream anti-glycolipid GD2 therapeutics for neuroblastoma (NB) have limitations, such as severe adverse effects, improved therapeutics are needed. In this study, we developed a GD2 aptamer (DB99) and constructed a GD2-aptamer-mediated multifunctional nanomedicine (ANM) with effective, precise, and biocompatible properties, which functioned both as chemotherapy and as gene therapy for NB. DB99 can bind to GD2 + NB tumor cells but has minimal cross-reactivity to GD2 − cells. Furthermore, ANM is formulated by self-assembly of synthetic aptamers DB99 and NB-specific MYCN small interfering RNA (siRNA), followed by self-loading of the chemotherapeutic agent doxorubicin (Dox). ANM is capable of specifically recognizing, binding, and internalizing GD2 + , but not GD2 − , NB tumor cells in vitro . Intracellular delivery of ANM activates Dox release for chemotherapy and MYCN-siRNA-induced MYCN silencing. ANM specifically targets, and selectively accumulates in, the GD2 + tumor site in vivo and further induces growth inhibition of GD2 + tumors in vivo ; in addition, ANM generates fewer or no side effects in healthy tissues, resulting in markedly longer survival with fewer adverse effects. These results suggest that the GD2-aptamer-mediated, targeted drug delivery system may have potential applications for precise treatment of NB.

show abstract

Antineoplastics

2021

Reactions Weekly

View full text Add to dashboard Cite

Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis

Cited by 3 publications

References 17 publications

Risk factors, impact and treatment of postoperative lymphatic leakage in children with abdominal neuroblastoma operated on by laparotomy

Risk factors, impact and treatment of postoperative lymphatic leakage in children with abdominal neuroblastoma operated on by laparotomy

A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics

Antineoplastics

Contact Info

Product

Resources

About